Reduced serum levels of Interleukin 17 in patients with osteonecrosis of the jaw and in multiple myeloma subjects after bisphosphonates administration.

作者信息

Oteri Giacomo, Allegra Alessandro, Bellomo Giacomo, Alonci Andrea, Nastro Enrico, Penna Giuseppa, Catalfamo Luciano, Cicciù Domenico, De Ponte Francesco Saverio, Musolino Caterina

出版信息

Cytokine. 2008 Aug;43(2):103-4. doi: 10.1016/j.cyto.2008.05.010. Epub 2008 Jun 27.

DOI:10.1016/j.cyto.2008.05.010

PMID:18585926

Abstract

摘要

相似文献

Reduced serum levels of Interleukin 17 in patients with osteonecrosis of the jaw and in multiple myeloma subjects after bisphosphonates administration.

Cytokine. 2008 Aug;43(2):103-4. doi: 10.1016/j.cyto.2008.05.010. Epub 2008 Jun 27.

The incidence of jaw osteonecrosis in multiple myeloma patients treated with bisphosphonates.

Acta Pol Pharm. 2006 Sep-Oct;63(5):450-2.

[Osteonecrosis of the jaw associated with the use of bisphosphonates in multiple myeloma: report of four cases and literature review].

Zhonghua Yi Xue Za Zhi. 2008 Nov 18;88(42):2986-7.

Osteonecrosis of the jaw and bisphosphonates.

N Engl J Med. 2005 Jul 7;353(1):99-102; discussion 99-102. doi: 10.1056/NEJM200507073530120.

[Avascular jaw osteonecrosis associated with bisphophonate therapy].

Recenti Prog Med. 2006 Mar;97(3):140-4.

Bisphosphonates induce apoptosis of circulating endothelial cells in multiple myeloma patients and in subjects with bisphosphonate-induced osteonecrosis of the jaws.

Acta Haematol. 2010;124(2):79-85. doi: 10.1159/000313787. Epub 2010 Jul 15.

Osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates: evidence of increased risk after treatment with zoledronic acid.

Haematologica. 2006 Jul;91(7):968-71. Epub 2006 Jun 1.

Why osteonecrosis of the jaw after bisphosphonates treatment is more frequent in multiple myeloma than in solid tumors.

J Oral Maxillofac Surg. 2006 Jun;64(6):995-6. doi: 10.1016/j.joms.2006.03.002.

[Osteonecrosis of the jaw in the course of multiple myeloma treatment and bisphosphonate administration].

Vnitr Lek. 2006 Feb;52(2):176-80.

[The complications during the therapy for multiple myeloma].

Vnitr Lek. 2006 Feb;52(2):115.

引用本文的文献

Arch Toxicol. 2024 Mar;98(3):689-708. doi: 10.1007/s00204-023-03653-7. Epub 2023 Dec 28.

Unexpected massive bleeding caused by extensive maxillary osteonecrosis in a breast cancer patient: a case report.

Transl Cancer Res. 2021 Nov;10(11):5014-5021. doi: 10.21037/tcr-21-404.

The Role of the Gut Microbiome in Pathogenesis, Biology, and Treatment of Plasma Cell Dyscrasias.

Front Oncol. 2021 Oct 1;11:741376. doi: 10.3389/fonc.2021.741376. eCollection 2021.

From Osteoclast Differentiation to Osteonecrosis of the Jaw: Molecular and Clinical Insights.

Int J Mol Sci. 2019 Oct 4;20(19):4925. doi: 10.3390/ijms20194925.

Targeting IL-17A in multiple myeloma: a potential novel therapeutic approach in myeloma.

Leukemia. 2016 Feb;30(2):379-89. doi: 10.1038/leu.2015.228. Epub 2015 Aug 21.

IL-17-mediated M1/M2 macrophage alteration contributes to pathogenesis of bisphosphonate-related osteonecrosis of the jaws.

Clin Cancer Res. 2013 Jun 15;19(12):3176-88. doi: 10.1158/1078-0432.CCR-13-0042. Epub 2013 Apr 24.

Bisphosphonate-related osteonecrosis of jaw (BRONJ): diagnostic criteria and possible pathogenic mechanisms of an unexpected anti-angiogenic side effect.

Vasc Cell. 2013 Jan 14;5(1):1. doi: 10.1186/2045-824X-5-1.

Elevated IL-17 produced by TH17 cells promotes myeloma cell growth and inhibits immune function in multiple myeloma.

Blood. 2010 Jul 1;115(26):5385-92. doi: 10.1182/blood-2009-10-246660. Epub 2010 Apr 15.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验